<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00092391</url>
  </required_header>
  <id_info>
    <org_study_id>V205C-007</org_study_id>
    <secondary_id>2004_073</secondary_id>
    <nct_id>NCT00092391</nct_id>
  </id_info>
  <brief_title>A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)</brief_title>
  <official_title>A Study of M-M-R(TM) II at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the mumps virus strength at the end of shelf-life
      (expiration date) of an approved vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 1999</start_date>
  <completion_date type="Actual">July 2001</completion_date>
  <primary_completion_date type="Actual">July 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neutralizing antibodies to mumps at 6 weeks postvaccination</measure>
    <time_frame>6 weeks postvaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titers to mumps by ELISA at 6 weeks and at 1 year postvaccination</measure>
    <time_frame>6 weeks and 1 year postvaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1997</enrollment>
  <condition>Measles</condition>
  <condition>Mumps</condition>
  <condition>Rubella</condition>
  <condition>Varicella</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>M-M-R(TM) II at current release potency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mumps Expiry Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>M-M-R(TM) II at intermediate expiry potency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mumps Expiry Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>M-M-R(TM) II at expiry potency</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live</intervention_name>
    <description>0.5 mL subcutaneous injection of one of three sub-lots on Day 0</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Mumps Expiry Group 1</arm_group_label>
    <arm_group_label>Mumps Expiry Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)</intervention_name>
    <description>0.5 mL subcutaneous injection on Day 0</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Mumps Expiry Group 1</arm_group_label>
    <arm_group_label>Mumps Expiry Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy children 12 to 18 months of age

        Exclusion Criteria:

          -  History or prior exposure to measles, mumps, rubella or varicella

          -  History of anaphylactoid reactions or hypersensitivity to any component of the
             vaccine, including gelatin and neomycin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>18 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2004</study_first_submitted>
  <study_first_submitted_qc>September 24, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2004</study_first_posted>
  <last_update_submitted>October 22, 2015</last_update_submitted>
  <last_update_submitted_qc>October 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rubella</mesh_term>
    <mesh_term>Mumps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

